Clarus Announces Initiation of Phase 4 Clinical Trial of JATENZO® (testosterone undecanoate) for the Treatment of Hypogonadal Men with Chronic Kidney Disease
March 16, 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first and only FDA-approved oral softgel for testosterone (T) replacement therapy in adult males who have deficient T due to certain medical conditions Clarus expects to announce...